



INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES

ABSTRACT OF THE DISCLOSURE

The present invention is directed to hydrazono compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula:



I



II

or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R¹ to R⁸ and X are as defined herein.